HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BRD 7389

a protein kinase inhibitor; structure in first source

Also Known As:

BRD-7389; BRD7389

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        BRD 7389: 1

Experts

1.	Bosenberg, Marcus W: 1 article (10/2017)
2.	Langdon, Casey G: 1 article (10/2017)
3.	Means, Robert: 1 article (10/2017)
4.	Micevic, Goran: 1 article (10/2017)
5.	Stern, David F: 1 article (10/2017)
6.	Theodosakis, Nicholas: 1 article (10/2017)
7.	Ventura, Alessandra: 1 article (10/2017)

Related Diseases

1.

Melanoma (Melanoma, Malignant)

10/01/2017 - "We sought to evaluate inhibitors of p90RSK family members: BI-D1870 and BRD7389, for their ability to inhibit both proliferation and protein synthesis in patient-derived melanoma cell lines with acquired resistance to combined treatment with the BRAF inhibitor vemurafenib and the mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor selumetinib. "

Related Drugs and Biologics

1.	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)
2.	Mitogen-Activated Protein Kinases
3.	Proteins (Proteins, Gene)
4.	Vemurafenib
5.	AZD 6244
6.	BI D1870